US Stock Market Movement: BioNTech plunges on October 13 as BNT113 fails to meet PFS endpoint

BioNTech October 13 Major Drop Analysis

Keywords: BNT113 did not meet PFS endpoint

On October 13, 2026, BioNTech announced the results of the AHEAD-MERIT phase 2/3 trial. BNT113 combined with pembrolizumab did not show a significant improvement in progression-free survival compared to pembrolizumab monotherapy, and did not achieve the first dual primary endpoint; overall survival is still under evaluation. These results indicate that the candidate therapy has not yet shown a statistically significant advantage in the primary efficacy endpoint.

(Disclaimer: This content is summarized from publicly available information collected by AI technology, for reference only and does not constitute investment advice.)